We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biodegradable Microneedle Patch Automates Tuberculosis Skin Testing

By LabMedica International staff writers
Posted on 04 Sep 2013
A patch comprising biodegradable microneedles has been developed that may replace the classical hypodermic needle tuberculin diagnostic test for tuberculosis.

The standard diagnostic test for tuberculosis (termed the Mantoux technique) is based on an intradermal injection of tuberculin, which is a species-nonspecific glycerol extract of the tubercle bacillus obtained from filtrates of sterilized, concentrated cultures. More...
A person who has been exposed to tuberculosis bacteria is expected to mount an immune response in the skin containing the bacterial proteins. The reaction is read by measuring the diameter of induration (palpable raised, hardened area) across the forearm (perpendicular to the long axis) in millimeters.

However, the standard diagnostic test is difficult to perform, since obtaining a correct diagnosis depends on the hypodermic needle being inserted into the arm of the patient at a precise angle and depth.

Investigators at the University of Washington (Seattle, USA) recently reported development of a technique that promises to be a significant improvement to the Mantoux technique. They created a patch containing biodegradable chitin microneedles. Each needle is 750 micrometers long and is coated with tuberculin solution.

The patch test was evaluated on guinea pigs, and results showed that following insertion of the microneedles, the positive skin reaction associated with having a tuberculosis infection was identical to that obtained when using the standard hypodermic needle test.

"It is like putting on a bandage," said senior author Dr. Marco Rolandi, assistant professor of materials science and engineering at the University of Washington. "As long as the patch is applied on the skin, the test is always delivered to the same depth underneath the skin. With a microneedle test there is little room for user error, because the depth of delivery is determined by the microneedle length rather than the needle-insertion angle. This test is painless and easier to administer than the traditional skin test with a hypodermic needle."

The guinea pig study was published in the August 26, 2013, online edition of the journal Advanced Healthcare Materials.

Related Links:
University of Washington



Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more

Molecular Diagnostics

view channel
Image: Researchers found that tumor DNA fragments in blood can reveal ongoing prostate cancer growth even when current tests show little change (image credit: Adobe Stock)

Blood Test Detects Early Nonresponse in Metastatic Prostate Cancer

Prostate cancer is the most common cancer in the U.K., with more than 64,000 men diagnosed and 12,000 deaths each year. For the roughly 10,000 men annually with advanced disease, early assessment of treatment... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.